An Orthogonal Approach for Comprehensive AAV Characterization
30 May 2024

As the field of gene therapy progresses, processes to produce this life-changing therapy may introduce impurities that can significantly impact its performance and quality.

Join Dr. Ben Draper, analytical lead at MegaDalton Solutions and Dr. Dr. Sophia Kenrick, head of analytical services at Waters|Wyatt Technology, for a deep dive into tackling critical impurities, particularly empty AAV capsids. Discover how size exclusion chromatography with UV and multiangle light scattering (SEC-MALS) can be optimized to ensure accurate measurements.

They will also explore the full-to-empty ratio as well as the quantification of partials using charge detection mass spectrometry (CDMS). Find out how SEC-MALS and CDMS can revolutionize analytical development and quality control testing. Plus, learn how the standard AAV Method Implementation and Training Service, as well as SOP Guidance Manual, can facilitate the adoption of advanced technology as a platform method for AAV development and production.

Key learning objectives

  • Understand the application of multi-angle light scattering coupled to size exclusion chromatography (SEC-MALS) for determining:
    • Molar mass
    • Aggregation
    • Empty/Full analysis
    • Titer of the capsid and genome
  • Gain insights into the use of charge detection mass spectrometry for analyzing partial capsids
  • Explore the advantages of employing orthogonal techniques for ccomprehensive AAV characterization

Who should attend?

Scientists working in the field of gene therapy characterization, formulation, and process development.

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Waters | Wyatt Technology